Differential Effects of Pioglitazone on Metabolic Parameters in Newly Diagnosed, Drug-Naïve Japanese Patients with Type 2 Diabetes with or Without Metabolic Syndrome

REFERENCES

• Rajaram V, Pandhya S, Patel S, Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 2004;93(11A):32C–48C.
   Google Scholar
• Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA, American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004;24(2):e19–e24.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Forlani G, Cerrelli F, WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004;21(4):383–387.
   PubMed Web of Science ®Google Scholar
• Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 2003;3(3):201–206.
   PubMedGoogle Scholar
• Barzilai N, She L, Liu BQ, Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999;48(1):94–98.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963–1972.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27(3):305–313.
   PubMed Web of Science ®Google Scholar
• Isley WL. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2003;2(6):581–586.
   PubMedGoogle Scholar
• Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7(2):369–379.
   PubMedGoogle Scholar
• Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005;7(2):161–169.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89(12):6068–6076.
   PubMed Web of Science ®Google Scholar
• Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004;6(2):133–156.
   PubMed Web of Science ®Google Scholar
• Campbell IW. Long-term glycemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58(2):192–200.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279–1289.
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Schneider CA, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 2006;4(4):445–459.
   PubMedGoogle Scholar
• Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori 1999;47(10):901–908.
   PubMedGoogle Scholar
• Harris MI. Classification and diagnostic criteria for diabetes mellitus and other categories of glucose intolerance. Prim Care 1988;15(2):205–225.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412–419.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1487–1495.
   PubMed Web of Science ®Google Scholar
• Gorla-Bajszczak A, Siegrist-Kaiser C, Boss O, Burger AG. Meier CA Expression of peroxisome proliferator-activated receptors in lean and obese Zucker rats. Eur J Endocrinol 2000;142(1):71–78.
   PubMed Web of Science ®Google Scholar
• Sewter C, Blows F, Considine R, Vidal-Puig A, O'Rahilly S. Differential effects of adiposity on peroxisomal proliferator-activated receptor gamma1 and gamma2 messenger ribonucleic acid expression in human adipocytes. J Clin Endocrinol Metab 2002;87(9): 4203–4207.
   PubMed Web of Science ®Google Scholar
• Eiji K. Glucose lowering effect of pioglitazone may be mediated through increased insulin levels as well as decreased insulin resistance. Ther Res 2006;27(4):719–723.
   Google Scholar
• Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy?. Am Heart J 2004;148(2):211–221.
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;115(Suppl. 8A):111S–115S.
   PubMedGoogle Scholar
• Ryan EH Jr, Han DP, Ramsay RC, Diabetic macular edema associated with glitazone use. Retina 2006;26(5):562–570.
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004;6(6):850–863.
   PubMedGoogle Scholar
• Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diab Vasc Dis Res 2005;2(2):61–66.
   PubMedGoogle Scholar
• Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22(8):986–993.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89(12): 6068–6076.
   PubMed Web of Science ®Google Scholar
• Schwartz AV. TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008;2008:297893.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice?. Expert Opin Drug Saf 2009;8(1):15–32.
   PubMed Web of Science ®Google Scholar
• Araki T, Emoto M, Yokoyama H, Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes. Osaka City Med J 2005;51(1):19–25.
   PubMedGoogle Scholar
• Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes 1989;38(6):784–792.
   PubMed Web of Science ®Google Scholar
• Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84(1):137–144.
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40(11):1286–1292.
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Furuta S, Shimajiri N, Nanjo T, Sanke T. Prevalence of metabolic syndrome in patients with type 2 diabetes, Abstract no W67 from 2005 Japan Diabetes Complication Society Meeting: Tokyo, Japan
   Google Scholar
• Report from 2007 National Health Research by the Ministry of Health, Labor and Welfare Japan. http://www.mhlw.go.jp/wp/hakusyo/kousei/07-3/kousei-data/PDF/030220.pdf accessed March 2007.
   Google Scholar
• Caranti DA, Lazzer S, Dâmaso AR, Prevalence and risk factors of metabolic syndrome in Brazilian and Italian obese adolescents: a comparison study. Int J Clin Pract 2008;62(10):1526–1532.
   PubMed Web of Science ®Google Scholar